Supplementary Figure 1. Dose-response matrices and Bliss drug synergy landscapes for the 50 drug pairs. The total number of drug combinations is 70 due to replicates.

Supplementary Figure 2. Histograms of the Bliss drug synergy scores, where the dasatinib-sorafenib combination is highlighted as a red bar.

Supplementary Figure 3. Interpretation of the network connectivity for the MDA-MB-231 drug combination network. (A) The predicted sensitivities for drug pairs that include BI 2536 (BI 2536 drug group) versus the others. (B) The predicted sensitivities for drug pairs that break the network (Group 1) versus the others (Group 2).

Supplementary Figure 4. %inhibition and %toxicity for *AURKB* siRNAs, *ZAK* siRNAs and their combinations. (A) Qiagen siRNAs and CellTiter-Glo readouts. (B) Ambion siRNAs and CellTiter-Glo readouts. (C) Ambion siRNAs and CellTox Green readouts. (D) The western blot gel images.

Supplementary Figure 5. %inhibition and %toxicity for *AURKB* sgRNAs, *ZAK* sgRNAs and sgRNA combinations in CRISPR/Cas9 screen.

Supplementary Figure 6. % inhibition and % toxicity for the Aurora B kinase inhibitors + *ZAK* siRNAs combination experiments for MDA-MB-361 and MDA-MB-436 cells.


Supplementary Figure 7. The RPKM values for the genes in the MDA-MB-231 specific signaling network, in relation to the distribution of all 675 cell lines reported in Klijn et al.²⁴.


Supplementary Figure 8. The ZAK and AURKB gene expression levels in TNBC versus non-TNBC cell lines from the Klijn et al. study²⁴.


Supplementary Figure 9. The Kaplan-Meier plot for the overall survival of TNBC patients with up-regulated AURKB expression (Z-score >2), down-regulated CSF1R (Z-score <0) and TP53 mutation (median months survival = 114, n = 17), as compared to the other TNBC patients (median


months survival not reached, n=100). P-value = 0.68 by Fleming-Harrington test with weights p=1 and q=1.


Supplementary Figure 10. The Kaplan-Meier plot for the overall survival of TNBC patients with up-regulated MAP2K3 or MAPK11 (median months survival = 37.8, n = 20, Gene expression Z-score > 2) as compared to the other TNBC patients (median months survival = 114.1, n = 96).

















































































































































































































Supplementary Figure 2





Supplementary Figure 3 В p < 0.0001p < 0.00011.0 1.0 Predicted Sensitivity Predicted Sensitivity 8.0 8.0 0.6 0.6 0.4 0.4 0.2 0.2 0.0 0.0 BI 2536 drug group Others Group 1 Group 2



Supplementary Figure 5







Supplementary Figure 8

